Intratumoral Ipilimumab

Phase 1Monoclonal antibody

Intratumoral Ipilimumab is one of 41 small molecule programs targeting Head and Neck Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CancerActive, not recruiting

Head and Neck CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Head and Neck Cancer

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Keytruda

Merck & Co.

Phase 3

18 3

Erbitux

IImclone

Phase 3

45 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

62 5

Neurontin

VViatris Specialty LLC

Approved

4 6

Oxycontin

PProtega

Approved

2 7

Opdivo

Bristol-Myers Squibb

Phase 3

10 8

Tylenol

KKenvue Brands

Approved

1 9

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 10

Marcaine

IInnocoll

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Head and Neck Cancer1 trial

Ipilimumab for Head and Neck Cancer Patients

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT02812524·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intratumoral Ipilimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intratumoral Ipilimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intratumoral Ipilimumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Providence Health & Services company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: PProvidence Health & Services

Intratumoral Ipilimumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News